MedTrace Logo

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02099136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-12-29

No results posted yet for this study

Summary

This randomized clinical trial studies if celecoxib will prevent the damaging effects of sunburn in healthy volunteers. Exposure to ultraviolet light can induce erythema, sunburn or skin redness caused by inflammation. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers. Studying samples of skin in the laboratory from patients receiving ultraviolet-radiation before and after celecoxib treatment may help doctors learn more about the effects celecoxib has on cells.

Conditions

  • No Evidence of Disease

Interventions

PROCEDURE

UV Light Therapy

Undergo UV-irradiation

OTHER

Placebo

Given PO

DRUG

Celecoxib

Given PO

PROCEDURE

Biopsy

Undergo skin biopsy

OTHER

Imaging Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Alice Pentland · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2001-09-30
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099136 on ClinicalTrials.gov